Clover Health Q2 revenue rises 56%, beating estimates on memership growth
Clover Health Q2 revenue rises 56%, beating estimates on memership growth
Overview
US Medicare Advantage insurer's Q2 revenue rose 56% yr/yr, beating analyst expectations
Adjusted EBITDA for Q2 rose 139% yr/yr, beating analyst expectations
Company raised full-year 2026 guidance across all metrics
Outlook
Clover Health raises 2026 revenue guidance to $2.92 bln-$3.00 bln
Company expects 2026 GAAP Net Income of $20 mln-$35 mln
Management sees increasing confidence for 2027 outlook due to strong cohort development
Result Drivers
MEMBERSHIP GROWTH - Co said Q2 Medicare Advantage membership rose 48% yr/yr, driving revenue growth
TECHNOLOGY PLATFORM EXPANSION - Co said wider adoption of AI-powered Clover Assistant platform enabled earlier intervention and improved health outcomes
COHORT ECONOMICS - Co said improved cohort economics and clinical engagement contributed to profitability and raised guidance
Company press release: ID:nGNX44QR0D
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $743 mln | $728.27 mln (3 Analysts) |
Q2 Net Income |
| $28 mln |
|
Q2 Adjusted EBITDA | Beat | $41 mln | $30.72 mln (3 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the managed healthcare peer group is "buy."
Wall Street's median 12-month price target for Clover Health Investments, Corp. is $4.13, about 3.4% below its August 4 closing price of $4.27
The stock recently traded at 152 times the next 12-month earnings vs. a P/E of 2,613 three months ago
Reuters Recommended Reads
Aug 5 - CVS Health Q2 revenue beats estimates, outlook raised
Aug 4 - eHealth Q2 revenue slightly exceeds analyst expectations
Aug 4 - Hinge Health Q2 revenue jumps 53%, beats estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)